CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis
dc.creator | Sokratous M., Dardiotis E., Bellou E., Tsouris Z., Michalopoulou A., Dardioti M., Siokas V., Rikos D., Tsatsakis A., Kovatsi L., Bogdanos D.P., Hadjigeorgiou G.M. | en |
dc.date.accessioned | 2023-01-31T09:58:41Z | |
dc.date.available | 2023-01-31T09:58:41Z | |
dc.date.issued | 2018 | |
dc.identifier | 10.1007/s12031-018-1046-x | |
dc.identifier.issn | 08958696 | |
dc.identifier.uri | http://hdl.handle.net/11615/79170 | |
dc.description.abstract | DNA methylation may predispose to multiple sclerosis (MS), as aberrant methylation in the promoter regions across the genome seems to underlie several processes of MS. We have currently determined the methylation status of eight genes in relapsing-remitting MS patients. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was used to determine the status of 31 CpG islands, located across eight genes, in 33 healthy individuals and 66 MS patients (33 in relapse and 33 in remission). The methylation levels in the examined sites ranged from 0 to 31%. Methylation positivity for RUNX3 and CDKN2A differed significantly between MS patients and healthy controls. Maximum methylation in RUNX3, CDKN2A, SOCS1, and NEUROG1 genes was significantly different between patients and controls. Roc curves demonstrated that the appropriate cut-offs to distinguish patients from healthy controls were 2% for RUNX3 (OR 3.316, CI 1.207–9.107, p = 0.024) and 3% for CDKN2A (OR 3.077, CI 1.281–7.39, p = 0.018). No difference in methylation was observed between patients in relapse and patients in remission, in any of the genes examined. Methylation patterns of RUNX3 and CDKN2A may be able to distinguish between MS patients and healthy controls, but not between MS patients in relapse and in remission. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Journal of Molecular Neuroscience | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042933057&doi=10.1007%2fs12031-018-1046-x&partnerID=40&md5=af7984e178bbbc65f208d22eae6524db | |
dc.subject | biological marker | en |
dc.subject | cacna1g protein | en |
dc.subject | cellular retinoic acid binding protein 1 | en |
dc.subject | cyclin dependent kinase inhibitor 2A | en |
dc.subject | genomic DNA | en |
dc.subject | MutL protein homolog 1 | en |
dc.subject | neurogenin 1 | en |
dc.subject | peptides and proteins | en |
dc.subject | somatomedin B | en |
dc.subject | suppressor of cytokine signaling 1 | en |
dc.subject | transcription factor RUNX3 | en |
dc.subject | unclassified drug | en |
dc.subject | basic helix loop helix transcription factor | en |
dc.subject | biological marker | en |
dc.subject | CDKN2A protein, human | en |
dc.subject | cyclin dependent kinase inhibitor 2C | en |
dc.subject | nerve protein | en |
dc.subject | NEUROG1 protein, human | en |
dc.subject | Runx3 protein, human | en |
dc.subject | SOCS1 protein, human | en |
dc.subject | suppressor of cytokine signaling 1 | en |
dc.subject | transcription factor RUNX3 | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | controlled study | en |
dc.subject | CpG island | en |
dc.subject | DNA methylation | en |
dc.subject | epigenetics | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | molecular genetics | en |
dc.subject | multiple sclerosis | en |
dc.subject | multiplex ligation dependent probe amplification | en |
dc.subject | observational study | en |
dc.subject | relapse | en |
dc.subject | remission | en |
dc.subject | adolescent | en |
dc.subject | blood | en |
dc.subject | case control study | en |
dc.subject | genetics | en |
dc.subject | middle aged | en |
dc.subject | multiple sclerosis | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Basic Helix-Loop-Helix Transcription Factors | en |
dc.subject | Biomarkers | en |
dc.subject | Case-Control Studies | en |
dc.subject | Core Binding Factor Alpha 3 Subunit | en |
dc.subject | CpG Islands | en |
dc.subject | Cyclin-Dependent Kinase Inhibitor p18 | en |
dc.subject | DNA Methylation | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Multiple Sclerosis, Relapsing-Remitting | en |
dc.subject | Nerve Tissue Proteins | en |
dc.subject | Suppressor of Cytokine Signaling 1 Protein | en |
dc.subject | Springer New York LLC | en |
dc.title | CpG Island Methylation Patterns in Relapsing-Remitting Multiple Sclerosis | en |
dc.type | journalArticle | en |
Αρχεία σε αυτό το τεκμήριο
Αρχεία | Μέγεθος | Τύπος | Προβολή |
---|---|---|---|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |